• A population pharmacokinetic model for carbamazepine in Chinese epileptic patients was developed, identifying body weight, age, and CYP3A5*3 genotype as significant covariates affecting clearance.
• CYP3A5*3 carriers exhibited 20% lower carbamazepine clearance, suggesting a need for dose adjustment in this genotype group.
• The model provides a basis for individualized carbamazepine dosing in Chinese patients, potentially improving therapeutic outcomes and reducing adverse effects.
• The study highlights the importance of pharmacogenetic factors in antiepileptic drug therapy and supports the integration of PopPK modeling in clinical practice.